再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

盘后交易 04-10 19:13:55 EDT

20.68

-0.06

-0.29%

盘后20.41

-0.27-1.31%

18:32 EDT

最高20.90	最低20.37	成交量49.34万
今开20.69	昨收20.74	日振幅2.53%
总市值22.95亿	流通市值22.62亿	总股本1.11亿
成交额1,020万	换手率0.45%	流通股本1.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":20.68,"timestamp":1775851200000,"preClose":20.74,"halted":0,"volume":493385,"hourTrading":{"tag":"盘后","latestPrice":20.41,"preClose":20.68,"latestTime":"18:32 EDT","volume":221,"amount":4551.620086,"timestamp":1775860331026,"change":-0.27,"changeRate":-0.013056,"amplitude":0.018859},"delay":0,"changeRate":-0.0028929604628736127,"floatShares":109371942,"shares":111000000,"eps":-1.602622,"marketStatus":"盘后交易","change":-0.06,"latestTime":"04-10 19:13:55 EDT","open":20.69,"high":20.895,"low":20.37,"amount":10197970.438845,"amplitude":0.025313,"askPrice":20.8,"askSize":50,"bidPrice":20.4,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.602622,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1775865600000},"marketStatusCode":4,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":20.74,"preHourTrading":{"tag":"盘前","latestPrice":21.1,"preClose":20.74,"latestTime":"08:55 EDT","volume":52,"amount":1085.189976,"timestamp":1775825737471,"change":0.36,"changeRate":0.017358,"amplitude":0.022662},"postHourTrading":{"tag":"盘后","latestPrice":20.41,"preClose":20.68,"latestTime":"18:32 EDT","volume":221,"amount":4551.620086,"timestamp":1775860331026,"change":-0.27,"changeRate":-0.013056,"amplitude":0.018859},"volumeRatio":0.651525,"impliedVol":0.9097,"impliedVolPercentile":0.868},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2624005385","title":"再鼎医药(09688)授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2624005385","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624005385?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:49","pubTimestamp":1775141352,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，公司于2026年4月1日(美国东部时间)根据2024年股权激励计划授出部分购股权、受限制股份单位以及业绩股份单位。授出可认购26.85万股美国存托股份的购股权、60.3851万股美国存托股份受限制股份单位及33,781股美国存托股份的业绩股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU2488822045.USD","BK4531","BK1574","BK4588","ZLAB","BK4139","BK1161","09688","BK4548","BK1588","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624222315","title":"再鼎医药宣布达成全球临床研究合作及供应协议，以评估创新性DLL3抗体药物偶联物Zocilurtatug Pelitecan与双特异性T细胞衔接器的联合治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2624222315","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624222315?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:58","pubTimestamp":1775102280,"startTime":"0","endTime":"0","summary":"再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。\" Zoci是靶向DLL3的 ADC，用于小细胞肺癌的治疗。关于Zocilurtatug Pelitecan  Zoci是再鼎医药全球肿瘤研发管线中一款靶向DLL3的新型ADC。Zoci已获得美国FDA授予的治疗SCLC的孤儿药资格认定和快速通道资格认定。IMDELLTRA是首款靶向DLL3的双特异性T细胞衔接器疗法，在上述患者中已验证具有总生存期获益。Zocilurtatug Pelitecan与IMDELLTRA的联合用药方案有望在此优势基础上，进一步改善有效性，同时保持可控的安全性[6]。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4924934_ZH24934_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4588","BK4585","ZLAB","BK4526","09688","BK4139","BK4531","BK1588","BK1574","LU2488822045.USD","BK4548","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624524927","title":"再鼎医药午前涨近5% 与安进公司达成一项全球临床研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624524927","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624524927?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:37","pubTimestamp":1775101020,"startTime":"0","endTime":"0","summary":"　　再鼎医药午前涨超4%，截至发稿，股价上涨4.82%，现报15.88港元，成交额2.88亿港元。　　作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-02/doc-inhtaraa1102717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09688","BK4585","BK4139","BK4531","BK4581","LU0889565916.HKD","SG9999001440.SGD","IE00B2B36J28.USD","BK4526","BK4548","LU0109394709.USD","LU1571399168.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU2089984988.USD","ZLAB","AMGN","LU0868494617.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU2242652126.USD","BK4588","BK4599","BK4566","LU1983299246.USD","IE0002141913.USD","LU0122379950.USD","LU2488822045.USD","LU2242646821.SGD","BK1588","BK1161","BK4534","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU0058720904.USD","LU2112291526.USD","LU1061106388.HKD","BK4533","LU0289739699.SGD","IE0009355771.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624452674","title":"港股再鼎医药涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624452674","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624452674?lang=zh_cn&edition=full","pubTime":"2026-04-02 09:58","pubTimestamp":1775095138,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月2日，再鼎医药(09688.HK)涨超4%，截至发稿涨4.22%，报15.79港元，成交额9800.73万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693054050.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"6c2eecd8186c1b91dbc836fcc084ea03","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693054050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK1588","BK1574","BK4526","09688","BK4585","BK1161","BK4588","VXUS","BK4139","ZLAB","BK4548","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622570897","title":"再鼎医药(09688)发布年度业绩 总收入同比增加15%至4.6亿美元 各产品管线进展积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2622570897","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622570897?lang=zh_cn&edition=full","pubTime":"2026-03-27 07:20","pubTimestamp":1774567240,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药 发布截至2025年12月31日止财政年度全年业绩，产品收入净额增加15%至4.57亿美元，主要是由于鼎优乐的销售增加及纽再乐的销售增加。每股基本及摊薄亏损为0.16美元。于2025年，公司的财务业绩持续强势，总收入较上年增加15%至4.6亿美元，而净亏损则减少32%至1.76亿美元。于2026年，公司预计收入将持续增长，主要得益于现有商业化产品以及近期获批并预计于今年内上市的产品或新适应证。公司的各产品管线方面亦继续取得进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药(09688)发布年度业绩 总收入同比增加15%至4.6亿美元 各产品管线进展积极","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","ZLAB","BK4139","BK1588","BK4526","BK4548","LU2488822045.USD","BK4585","BK1161","BK4588","09688","BK1574"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619546907","title":"再鼎医药(09688.HK)拟3月26日(美国东部时间)/3月27日(香港时间)举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2619546907","media":"中金财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619546907?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:07","pubTimestamp":1773670021,"startTime":"0","endTime":"0","summary":"格隆汇3月16日丨再鼎医药(09688.HK)公告，董事会将于2026年3月26日(星期四，美国东部时间)/2026年3月27日(星期五，香港时间)审议及批准(其中包括)根据香港联合交易所有限公司证券上市规则编制的公司及其附属公司截至2025年12月31日止年度的年度业绩及其发布。\r\n\r\n　　公司先前已公布其根据美国公认会计准则编制的年度业绩，并于2026年2月26日(星期四，美国东部时间/香港时间)以表格10-K向美国证券交易委员会(\"美国证交会\")提交其截至2025年12月31日止年度的年度报告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260316/32072706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1588","09688","BK4588","BK4139","LU2488822045.USD","BK1574","BK4548","ZLAB","BK4526","BK4585","BK1161","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619190413","title":"再鼎医药(09688)：授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2619190413","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619190413?lang=zh_cn&edition=full","pubTime":"2026-03-13 21:24","pubTimestamp":1773408240,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，本公司于授出日期根据2024年股权激励计划授出35.34万份购股权、3.24万股受限制股份单位以及17.54万股业绩股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU2488822045.USD","BK4531","BK1574","BK4588","ZLAB","BK4139","BK1161","09688","BK4548","BK1588","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618862761","title":"再鼎医药(09688)授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2618862761","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618862761?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:42","pubTimestamp":1773067323,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，公司于授出日期根据2024年股权激励计划授出可认购37.422万股美国存托股份的购股权、12.162万股美国存托股份受限制股份单位以及18.2428万股美国存托股份的业绩股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","ZLAB","BK4531","BK4585","BK1574","09688","BK4526","LU2488822045.USD","BK1588","BK4548","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617526522","title":"再鼎医药(09688)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2617526522","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617526522?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:54","pubTimestamp":1772722453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于授出日期根据2024年股权激励计划向4名承授人授出可认购合共8万股美国存托股份的购股权并向9名承授人授出涉及合共12.344万股美国存托股份的受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","ZLAB","LU2488822045.USD","BK1588","BK4526","BK1574","BK4531","BK4548","BK1161","BK4585","09688","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617752571","title":"再鼎医药(09688)：Moulder已调任董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2617752571","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617752571?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:39","pubTimestamp":1772721583,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，Leon O. Moulder, Jr.先生已调任公司董事，自本公告之日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","09688","BK1574","ZLAB","LU2488822045.USD","BK1161","BK4585","BK4139","BK4526","BK1588","BK4548","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614009658","title":"再鼎医药绩后高开近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614009658","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614009658?lang=zh_cn&edition=full","pubTime":"2026-02-27 09:40","pubTimestamp":1772156431,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月27日，再鼎医药(09688.HK)绩后高开近5%，截至发稿涨4.9%，报15.19港元，成交额204.58万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602273656364575.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656364575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK1588","BK1574","BK4526","09688","BK4585","BK1161","BK4588","BK4139","ZLAB","BK4548","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128119023","title":"港股创新药概念股走强！药明合联涨超7%，云顶新耀、再鼎医药涨近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128119023","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128119023?lang=zh_cn&edition=full","pubTime":"2026-02-27 09:40","pubTimestamp":1772156400,"startTime":"0","endTime":"0","summary":"2月27日，港股创新药概念股走强，$药明合联(02268)$涨超7%，$云顶新耀(01952)$、$再鼎医药(ZLAB)$涨近6%，$康方生物(09926)$、$药明生物(02269)$涨超4%，$歌礼制药-B(01672)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9a5adfc15d956a00313fe91052a1cff8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4548","BK1141","ZLAB","BK1588","LU2488822045.USD","BK1161","159992","01952","BK1583","VXUS","02268","BK4531","SG9999014674.SGD","BK4526","VT","BK4139","BK1574","BK4588","06978","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614006412","title":"港股异动 | 再鼎医药(09688)绩后高开近5% 去年总收入同比增长15% KarXT计划于26年上半年商业化上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2614006412","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614006412?lang=zh_cn&edition=full","pubTime":"2026-02-27 09:27","pubTimestamp":1772155657,"startTime":"0","endTime":"0","summary":"再鼎医药(09688)绩后高开近5%，截至发稿，涨4.9%，报15.19港元，成交额204.58万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260227/20260227092854_51953.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260227/20260227092854_51953.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","ZLAB","BK1161","BK4585","LU2488822045.USD","VXUS","BK1574","09688","BK4531","BK4526","BK4139","BK1588","VT","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614404418","title":"再鼎医药(09688)2025年总收入为4.602亿美元 同比增长15% 全球创新管线取得显著进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2614404418","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614404418?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:00","pubTimestamp":1772110835,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药 发布公告，2025年第四季度总收入为1.276亿美元，同比增长17%;2025年全年总收入为4.602亿美元，同比增长15%。2025年第四季度净亏损为5040.9万美元，同比收窄38.29%;2025年全年净亏损为约1.755亿美元，同比收窄31.73%。截至2025年12月31日，现金及现金等价物、短期投资和流动受限制现金总计为7.896亿美元。2025年全年研发开支为2.209亿美元，2024年同期为2.345亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","ZLAB","BK4548","LU2488822045.USD","BK4139","BK4526","09688","BK4531","BK4588","BK1161","BK4585","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611937183","title":"港股异动 | 再鼎医药(09688)再涨超5% ZL-1310拟纳入突破性疗法 有望成为SCLC治疗领域突破性疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2611937183","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611937183?lang=zh_cn&edition=full","pubTime":"2026-02-13 10:52","pubTimestamp":1770951178,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药再涨超5%，截至发稿，涨5.1%，报15.26港元，成交额8197.41万港元。消息面上，2月9日，再鼎医药的注射用ZL-1310拟纳入突破性疗法，拟用于一线含铂治疗期间或治疗后出现疾病进展的广泛期小细胞肺癌患者。ZL-1310在早期临床研究中展现出的疗效数据非常突出，尤其是在二线及以上治疗和脑转移患者中均显示出高缓解率，使其有潜力成为SCLC治疗领域的突破性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","09688","BK4588","BK4139","LU2488822045.USD","BK1574","BK4548","VT","ZLAB","BK4526","BK4585","BK1161","VXUS","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610195534","title":"再鼎医药(09688.HK)拟于2月26日审议及发布2025年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2610195534","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610195534?lang=zh_cn&edition=full","pubTime":"2026-02-11 22:07","pubTimestamp":1770818826,"startTime":"0","endTime":"0","summary":"格隆汇2月11日丨再鼎医药(09688.HK)公布，公司董事会将于2026年2月26日(星期四)审议及批准(其中包括)根据美国公认会计准则(“美国公认会计准则”)及美国证券交易委员会(“美国证交会”)的适用规则编制的公司及其附属公司截至2025年12月31日止年度的财务业绩(“年度业绩”)及其发布。\r\n\r\n　　倘年度业绩获董事会批准，公司将于2026年2月26日(星期四)在香港联合交易所有限公司网站www.hkexnews.hk及公司网站http://ir.zailaboratory.com发布关于年度业绩的公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260211/32013321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09688","BK4548","BK4585","BK1588","BK1161","BK4139","BK4531","ZLAB","BK4588","BK4526","LU2488822045.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608936821","title":"摩根大通增持再鼎医药(09688)约192.01万股 每股作价约13.34港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608936821","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608936821?lang=zh_cn&edition=full","pubTime":"2026-02-04 19:00","pubTimestamp":1770202840,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，1月30日，摩根大通增持再鼎医药(09688)192.0096万股，每股作价13.3426港元，总金额约为2561.91万港元。增持后最新持股数目约为5647.03万股，最新持股比例为5.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1670628061.USD","LU0345770308.USD","LU2213496289.HKD","09688","IE00BFXG1179.USD","LU2237443978.SGD","ZLAB","LU0496365809.HKD","LU0882574139.USD","LU2237443549.SGD","BK1574","LU2505996681.GBP","LU0976567544.SGD","LU1974910355.USD","LU2746668461.USD","LU2756315664.SGD","LU2242649171.HKD","LU2211815571.USD","IE00B775SV38.USD","LU1244550494.USD","LU1720051017.SGD","LU1496350171.SGD","LU1894683264.USD","LU1988902786.USD","LU1720051108.HKD","BK4139","LU2552382215.SGD","IE00BZ1G4Q59.USD","LU2264538146.SGD","LU1267930490.SGD","LU1894683348.USD","LU1668664300.SGD","LU1366192091.USD","IE00BKDWB100.SGD","BK4533","LU0070302665.USD","LU2023250843.SGD","LU0964807845.USD","BK4531","BK1588","LU0320765489.SGD","IE00B3S45H60.SGD","LU0267386448.USD","LU1244550221.USD","LU1548497426.USD","LU1363072403.SGD","LU1032466523.USD","IE00BDCRKT87.USD","LU2505996509.AUD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608858816","title":"【券商聚焦】浦银国际维持再鼎医药(09688)“买入”评级 料公司有望在2027年迎来净利润端的盈亏平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2608858816","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608858816?lang=zh_cn&edition=full","pubTime":"2026-02-02 14:59","pubTimestamp":1770015599,"startTime":"0","endTime":"0","summary":"基于公司近况以及短中期商业化展望，该机构将2025E/2026E净亏损预测调整为1.9亿美元/2.1亿美元，该机构预计公司有望在2027年迎来净利润端的盈亏平衡。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974391","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZLAB","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607089064","title":"海通国际：维持再鼎医药(09688)“优于大市”评级 双引擎助力实现长期全球价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2607089064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607089064?lang=zh_cn&edition=full","pubTime":"2026-01-30 10:58","pubTimestamp":1769741898,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海通国际发布研报称，维持再鼎医药“优于大市”评级，对应目标价为35.25港元，该行调整2025-2027年收入预测至4.7/5.0/7.2亿美元，一方面通过引进并商业化海外产品获取稳定收入，另一方面依托跨境平台推动创新管线全球开发。此外，管理层预计一项新型联合用药方案的I期临床研究预计于2026年上半年启动。公司预计在2026年下半年公布用于健康受试者的首次人体研究数据。管理层预计将于年内完成临床试验申报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ZLAB","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603937939","title":"2026年JPM大会诺华、阿斯利康、辉瑞等巨头超百亿美元交易频现，中国资产成最大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937939","media":"药厂那点事儿","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603937939?lang=zh_cn&edition=full","pubTime":"2026-01-16 07:05","pubTimestamp":1768518317,"startTime":"0","endTime":"0","summary":"巨头交易频现，中国资产备受青睐。诺华公司周二下午宣布了一项针对中国生物技术公司泽璟生物的许可交易。再生元计划在2026年公布该药用于肥胖治疗的中国3期临床试验结果，并启动全球3期临床开发计划。截至2025年第三季度，19家大型制药公司现金储备总额超过1700亿美元，2025年前三季度产生了约1400亿美元的自由现金流，为大规模并购交易提供了充足的资金支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","ZLAB","BK1161","02268","01530","02269","09688","02615","06978","02359","AAPG","BK1191","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0162},{"period":"1month","weight":0.0658},{"period":"3month","weight":0.1181},{"period":"6month","weight":-0.3142},{"period":"1year","weight":-0.2336},{"period":"ytd","weight":0.1757}],"compareEarnings":[{"period":"1week","weight":0.0367},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0204},{"period":"6month","weight":0.0412},{"period":"1year","weight":0.2393},{"period":"ytd","weight":-0.0029}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.085823},{"month":2,"riseRate":0.555556,"avgChangeRate":0.030708},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.076257},{"month":4,"riseRate":0.444444,"avgChangeRate":0.018624},{"month":5,"riseRate":0.5,"avgChangeRate":0.028309},{"month":6,"riseRate":0.5,"avgChangeRate":0.075433},{"month":7,"riseRate":0.5,"avgChangeRate":0.004927},{"month":8,"riseRate":0.625,"avgChangeRate":0.000651},{"month":9,"riseRate":0.375,"avgChangeRate":-0.055585},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.047464},{"month":11,"riseRate":0.555556,"avgChangeRate":0.101421},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.029495}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}